How lung capillary surface area changes after balloon pulmonary angioplasty for CTEPH

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will measure functional pulmonary capillary surface area (FCSA) in people with CTEPH immediately before and after a session of balloon pulmonary angioplasty (BPA). The measurement uses trace quantities of 3H-benzoyl Phe-Ala-P to quantify capillary metabolic surface area in the lung. The protocol captures acute changes in downstream microvasculature associated with opening obstructed pulmonary artery segments. The single-center study is conducted at the Jewish General Hospital and excludes patients on ACE inhibitors or ARBs and those with a patent foramen ovale.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Exclusion Criteria:

* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
* Presence of patent foramen ovale

Where it's running

• David Langleben
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: David Langleben, MD
• Email: david.langleben@mcgill.ca
• Phone: 5143407531

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vasoactive Agents in Pulmonary Hypertension Crisis

  This trial tests whether dopamine, norepinephrine, or epinephrine can safely and effectively help people with a pulmonary hypertension crisis who are in the hospital.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality and 2 other locations · NCT07667829

• TX000045 for pulmonary hypertension from interstitial lung disease

  This study tests TX000045 to see if it can reduce pulmonary vascular resistance in people with PH caused by interstitial lung disease and to check its safety.

  Recruiting at 12 sites Phase 2 Tectonic Operating Company, Inc. · Phoenix, Arizona and 15 other locations · NCT07473700

• Using bedside electrical impedance tomography to detect pulmonary hypertension

  We will test whether a non-invasive bedside scan called electrical impedance tomography (EIT) can detect pulmonary hypertension in adults who are already having a right heart catheterization.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07453017

• Digital stethoscope and 3-lead ECG detection of pulmonary hypertension and low ejection fraction

  This project will test whether heart sounds and a three-lead ECG recorded with a digital stethoscope can find pulmonary hypertension or low left ventricular ejection fraction in adults having an echocardiogram.

  Recruiting at 4 sites Eko Devices, Inc. · O'Fallon, Illinois and 3 other locations · NCT07087613

• Deep-learning ECG to detect pulmonary hypertension

  This trial tests whether an AI-powered ECG can spot high blood pressure in the lungs (pulmonary hypertension) in adults aged 50–85 who have had a recent ECG.

  Recruiting National Defense Medical Center, Taiwan · Taipei · NCT07079592

• Identifying low-risk cancer patients with pulmonary embolism for early discharge from the emergency department

  This study is trying to find out which cancer patients with pulmonary embolism can safely go home early from the emergency department to avoid extra hospital time.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06761144

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.